单位:[1]Institut Curie, PSL Research University,CNRS, UMR 144, Paris F-75005, France[2]Department of Urology, Beijing Friendship Hospital, Capital MedicalUniveristy , Beijing, 430071, People’s Republic of China临床科室泌尿外科泌尿外科首都医科大学附属北京友谊医院[3]Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics,Huazhong Agricultural University, Wuhan 430070, People’s Republic of China[4]Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan,430071, People’s Republic of China[5]Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan430071, People’s Republic of China
Background: Bladder cancer is a common malignancy that affects the human urinary tract. Muscle-invasive bladder cancer (MIBC) is aggressive and has poor prognosis. Previous studies have reported that the tumor-infiltrating lymphocytes (TILs) were associated with MIBC outcome; however, inconsistency remains and mRNA level TIL markers' prognostic significance in MIBC is unclear. Materials and methods: In the present study, we reanalyzed data from four public datasets (the Cancer Genome Atlas for investigation; and CIT, GSE5287, and GSE31684 for validation) to examine the prognostic significance of CD3D, CD4, CD8A, CD3D/CD4 and CD3D/CD8A in MIBC. Results: We found that the CD3D/CD4 ratio was a stable independent prognostic factor in MIBC (beta = -0.87, P = 0.025); high CD3D/CD4 ratio predicted better survival in MIBC, and the power of this association was much stronger in basal-squamous tumors (beta = -4.73, P = 2.67E-06). We also noted that the CD4 expression was significantly higher than CD3D (P < 0.05), indicating the presence of CD3(-)CD4(+) cells which could be immune-suppressing. Conclusion: The CD3D/CD4 ratio can be viewed as a prognostic marker and a rough measurement for the interaction between immune-effecting CD3(+) TILs and immune-suppressing CD3(-)CD4(+) cells in MIBC, and this interaction may play a particularly important role in anti-cancer immunity in basal-squamous tumors as it has a very strong association with survival in this subtype, and may be used to select potential responders to immunotherapy.
基金:
Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2662018PY023]
第一作者单位:[1]Institut Curie, PSL Research University,CNRS, UMR 144, Paris F-75005, France[2]Department of Urology, Beijing Friendship Hospital, Capital MedicalUniveristy , Beijing, 430071, People’s Republic of China
通讯作者:
通讯机构:[3]Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics,Huazhong Agricultural University, Wuhan 430070, People’s Republic of China[4]Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan,430071, People’s Republic of China[5]Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan430071, People’s Republic of China[*1]Department of Oncology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, People’s Republic of China[*2]Department of Urology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan 430071, People’s Republic of China
推荐引用方式(GB/T 7714):
Shi Ming-Jun,Meng Xiang-Yu,Wu Qiu-Ji,et al.High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer[J].CANCER MANAGEMENT and RESEARCH.2019,11:2987-2995.doi:10.2147/CMAR.S191105.
APA:
Shi, Ming-Jun,Meng, Xiang-Yu,Wu, Qiu-Ji&Zhou, Xiong-Hui.(2019).High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer.CANCER MANAGEMENT and RESEARCH,11,
MLA:
Shi, Ming-Jun,et al."High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer".CANCER MANAGEMENT and RESEARCH 11.(2019):2987-2995